Effect of ashwagandha (<i>Withania somnifera</i>) extract with Sominone (Somin-On™) to improve memory in adults with mild cognitive impairment: A randomized, double-blind, placebo-controlled study
Rai HP, Mishra DN
Journal of psychopharmacology (Oxford, England) · 4 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2025-03-18 · J Psychopharmacol · vol. 39 · número 4 · págs. 350–363
- Editorial
- SAGE Publishing
- Citado
- 8 citas · más que el 98% de estudios similares · 9.0× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 69 trabajos
- Acceso
- De pago
- Áreas de investigación
- Phytochemicals and Medicinal Plants · Medicinal Plants and Neuroprotection · Pharmacology and Nanomedicine Research
- Palabras clave
- Wechsler Memory Scale, Placebo, Montreal Cognitive Assessment, Cognition, Randomized controlled trial, Wechsler Adult Intelligence Scale, Psychology, Audiology, Verbal memory, Working memory, Memory span, Placebo-controlled study, Medicine, Physical therapy, Cognitive impairment, Psychiatry, Double blind, Internal medicine
- MeSH
- humans, withania, plant extracts, treatment outcome, pilot projects, double-blind method, cognition, memory, neuropsychological tests, adult, aged, middle aged, female, male, cognitive dysfunction
2 autores
- Hari Prakash · autor de correspondencia
- Deo Nidhi Mishra🇮🇳Nirma (India)
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Mild cognitive impairment (MCI) is a condition in which people have memory or thinking problems than other people of their age. This study evaluated the effectiveness and safety of ashwagandha extract standardized with Sominone (Somin-On™) in enhancing memory and cognitive functioning in adults with MCI.
Methods
In this randomized double-blind, placebo-controlled pilot study, 40 subjects with MCI were randomized in a 1:1 ratio to receive either Somin-On™ (250 mg daily) or a placebo for 60 days. The outcome measures, improvement in memory and other cognitive functions after 30 and 60 days were assessed using Montreal Cognitive Assessment (MoCA); Mini-mental state examination (MMSE); Wechsler Memory Scale-III (WMS-III)); and Shepard mental rotation task.
Results
Subjects treated with Somin-On™ showed significant improvements in immediate memory, general memory, working memory and visuospatial processing and the response assessed using WMS-III after 30 and 60 days outperforming the placebo group. Scores on the Shepard Mental Rotation test in Somin-On™ group showed a significant rise by 12.22% at 30 days and 31.67% at 60 days, from baseline. Significant improvement was observed with Somin-On™ in memory assessment scales viz. MoCA (7.83% at 30 days and 14.77% at 60 days, from baseline) and MMSE (9.26% at 30 days and 19.21% at 60 days, from baseline) compared to placebo group.
Conclusions
The supplementation of Somin-On™ is an effective therapy to improve the immediate, general and working memory, as well as cognitive functions like attention and information processing speed in adults with MCI.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.